Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MN1
REST API REST API
Homo sapiens
MN1 is differentially expressed in 248 experiments: 130 organism parts: liver, brain, ... (128 more);, 177 disease states: normal, glioblastoma, ... (175 more);, 76 cell types 368 cell lines 33 compound treatments and 66 other conditions.
Synonyms MGCR1-PEN, MGCR1, MGCR
Orthologs MN1 (Bos taurus)   Mn1 (Mus musculus)   MN1 (2 of 2) (Danio rerio)   MN1 (1 of 2) (Danio rerio)   Mn1 (Rattus norvegicus)   mn1.2 (Xenopus laevis)   MN1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term biological_process, molecular_function, cellular_component, binding, intramembranous ossification
UniProt Accession A5HML1, Q10571
Gene-Disease Assocation MENINGIOMA, FAMILIAL
Search EB-eye ENSG00000169184
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-7224, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (30 experiments)

Factor Value U/D Experiments
DU145
2
E-GEOD-17482, E-GEOD-20089
MOLT4
2
E-MTAB-62, E-MTAB-37
MCF-7
1
2
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639
A375
1
E-MTAB-37
LP9
1
E-GEOD-21750
A549
1
E-GEOD-3202
362 more value(s).


Cell type

studied in E-TABM-40, E-GEOD-20193, E-MEXP-2426, E-GEOD-21668, E-GEOD-3920, ... (39 experiments)

Factor Value U/D Experiments
2
E-TABM-130, E-TABM-145
BDCA3+ dendritic cell
1
E-TABM-34
nucleus pulposus
1
E-MEXP-2488
CD56+ NK cells
1
E-AFMX-5
mesothelial cells
1
E-GEOD-21750
CD3- CD56dim CD62L+ NK cell
1
E-GEOD-21774
70 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-MEXP-1121, E-TABM-15, E-MTAB-62, ... (55 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-37, E-GEOD-2514, E-MTAB-62, E-MEXP-231
glioblastoma
1
3
E-GEOD-4290, E-MTAB-37, E-GEOD-4412, E-MEXP-567
prostate carcinoma
1
3
E-MTAB-62, E-MEXP-2034, E-GEOD-96, E-GEOD-5377
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
gastric carcinoma
2
E-MTAB-37, E-GEOD-2685
Burkitt's lymphoma
2
E-MTAB-37, E-GEOD-1880
171 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-GEOD-15205, E-GEOD-697, E-GEOD-5099, ... (21 experiments)

Factor Value U/D Experiments
none
2
4
E-MEXP-1958, E-GEOD-412, E-GEOD-5099, E-GEOD-995, E-GEOD-697, ... (6 experiments)
U0126
1
E-GEOD-697
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
TNF
1
E-GEOD-15205
non-steroidal anti-inflammatory drugs
1
E-GEOD-1919
AMP
1
E-MEXP-2285
27 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
53 years
1
E-GEOD-4922
53
1
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-2191, E-GEOD-2034, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-MTAB-62

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Genetic modification
studied in E-GEOD-7578, E-GEOD-20847, E-MEXP-563

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-TABM-868, E-GEOD-20115, E-MEXP-958, ... (13 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-MEXP-1220, E-TABM-127, E-GEOD-20504, E-MEXP-1446, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1432, E-GEOD-2466, E-GEOD-1926, ... (22 experiments)

Infection
studied in E-MEXP-561, E-GEOD-6802, E-GEOD-512

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-1493, E-GEOD-21750, E-GEOD-17636

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19246

Qpcr egfr dct
studied in E-GEOD-5851

Qrt pcr areg dct
studied in E-GEOD-5851

Qrt pcr ereg dct
studied in E-GEOD-5851

RNAi
studied in E-MEXP-2115, E-GEOD-1676, E-GEOD-3697, E-MEXP-1315, E-MEXP-2759 ... (5 experiments)

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7307, E-GEOD-1295

Stimulation
studied in E-GEOD-11886

Subtype
studied in E-GEOD-24283

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-19246, E-GEOD-13818, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561, E-GEOD-4922, E-TABM-147 ... (5 experiments)

Processing time: 0.262 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM